Cloud-Clone pitches flow cytometer multiplexing as a Luminex alternative

Cloud-Clone is positioning its CBA bead array technology as a way for labs to run high-plex protein assays on standard flow cytometers instead of proprietary multiplex platforms. The company says the approach avoids licensing limits and could tap an installed base of 150,000 to 200,000 instruments worldwide.

Why it matters: - Multiplex protein testing is central to systems biology, translational research and pre-clinical work. - Cloud-Clone says its CBA technology can turn existing flow cytometers into multiplex protein quantitation platforms without requiring dedicated proprietary hardware. - The pitch targets labs that want higher-throughput biomarker testing without licensing restrictions tied to closed systems.

What happened: - Cloud-Clone outlined its CBA, or Cytometric Bead Array, platform in a release dated Aug. 26, 2026. - The company described CBA as an alternative multiplex protein quantitation solution for standard flow cytometers. - Cloud-Clone framed the product as a response to practical barriers in adopting high-plex testing workflows.

The details: - The company says global flow cytometers total about 150,000 to 200,000 instruments across academic, medical, pharmaceutical and contract-research labs. - CBA uses fluorescence-encoded microspheres with capture antibodies attached to the beads. - After sample incubation, antigen-antibody sandwich complexes are loaded onto the flow cytometer. - The instrument reads bead fluorescent codes through the APC channel. - Protein concentration is calculated from fluorescence intensity measured through the PE channel. - Baseline assays require only APC and PE channels. - Testing more than 27 analytes at once requires an APC-Cy7 channel. - Cloud-Clone says no new hardware investment is needed for most commercially available flow cytometers. - The company says laboratories can buy CBA assay kits and run multiplex tests on existing hardware. - Cloud-Clone says the workflow is independent of Luminex’s patented instrument ecosystem. - Cloud-Clone says CBA is not bound by Luminex end-user license terms. - The company says there is no need to become an authorized development partner. - Cloud-Clone says its CBA system avoids hardware-reagent locking, restrictive license contracts and the risk of unilateral license termination. - The company says its in-house antibody library includes more than 27,000 entries. - Cloud-Clone says it develops and produces fluorescence-encoded microspheres, capture antibodies and matched detection-antibody pairs internally.

Between the lines: - The release is as much about workflow control as assay performance. - Cloud-Clone is trying to position standard flow cytometers as an installed base already available to most labs, which would lower adoption friction if the assays fit existing instruments. - The company is also arguing that proprietary multiplex systems create operational and supply-chain risk because consumables, software and service terms can be tied to one vendor. - The comparison to broader industry restrictions on specialized research hardware signals a concern that single-source platforms can create vulnerability if access to instruments or reagents changes.

What's next: - Cloud-Clone is betting that labs looking for multiplex biomarker testing will choose a path that avoids proprietary licensing and dedicated hardware. - The company says laboratories can use the platform on mainstream flow instruments from major manufacturers. - The broader test will be whether researchers see enough performance and workflow value to shift away from closed multiplex systems.

The bottom line: - Cloud-Clone is making a direct play for labs that already own flow cytometers and want multiplex testing without proprietary platform lock-in.